



Abstract

Pharmacological Modulation of Hif-1 α in the Cerebral Cortex of Rats after Chronic Prenatal Hypoxia [†]

Olena G. Aliyeva ^{1,*} , Igor F. Belenichev ², Olena O. Popazova ³  and Galina A. Zidrashko ³

¹ Department of Medical Biology, Parasitology and Genetics, Zaporizhzhia State Medical University, 69035 Zaporizhzhia, Ukraine

² Department of Pharmacology and Medical Formulation with Course of Normal Physiology, Zaporizhzhia State Medical University, 69035 Zaporizhzhia, Ukraine

³ Department of Histology, Cytology and Embryology, Zaporizhzhia State Medical University, 69035 Zaporizhzhia, Ukraine

* Correspondence: aliyeva1eg@gmail.com

[†] Presented at the 3rd International Electronic Conference on Brain Sciences (IECBS 2022), 1–15 October 2022; Available online: <https://iecb2022.sciforum.net/>.

Abstract: Despite the significant advances in modern medicine, the problem of perinatal hypoxic CNS damage in children occupies one of the leading places in modern neonatology. Hypoxic damage to the fetal brain is the cause of delayed psycho-linguistic and motor development, mental insufficiency, movement disorders, cerebral palsy, disability and severe cases of neonatal mortality. Chronic prenatal hypoxia (PH) leads to biochemical and structural changes in the developing brain and, as a consequence, to the pathological development of the fetal brain, the development of neurological deficit not only immediately after birth, but also in the late periods of postnatal ontogenesis. The protein factors identified in recent decades, which are involved in the mechanisms of urgent and long-term adaptation to hypoxia (HIF1), can serve as specific targets for pharmacological action, opening up promising opportunities for the search for new effective drugs for the treatment of hypoxic CNS lesions in children. The aim of the research: To study the ability of a number of drugs (cerebrocurin, angiolin, glutoredoxin, thiotriazoline, L-arginine, mexidol and piracetam) to modulate the level of HIF-1 α expression in the cerebral cortex of rats after chronic PH. Materials and methods: The studies were carried out on 90 male rats of two months of age, obtained from females in which, from the 16th day of pregnancy, chronic PH was modeled in the offspring. New-born animals were divided into 9 groups: 1st—intact animals obtained from females with normal physiological pregnancy, which received 1 mL of physiological solution; 2nd—control animals after PH, 3rd–9th groups—animals after PH, which after birth were intraperitoneally injected with the drug in an effective dose (cerebrocurin—150 μ L/kg, piracetam—500 mg/kg, angiolin—50 mg/kg, thiotriazoline—50 mg/kg, mexidol—100 mg/kg, L-arginine—200 mg/kg, glutoredoxin—200 μ g/kg, i. p). Real-time reverse transcription polymer chain reaction (RT-PCR) was used to assess the state of HIF-1 α expression. The results of the study were processed using the statistical package of the licensed program “STATISTICA for Windows 6.1”. The significance of differences between the experimental groups was assessed using the nonparametric Mann–Whitney U test. Differences with a significance level of more than 95% ($p < 0.05$) were considered significant. Results: It was found that in animals after PH, the expression level of HIF-1 α mRNA is 0.331 ± 0.0002 c.u., which is three times lower than in intact animals. Analysis of the results of the prolonged action of the studied preparations on the level of HIF-1 α mRNA expression shows that the use of the studied preparations led to an increase in the level of HIF-1 α mRNA expression, except for animals receiving L-arginine (0.37 ± 0.001 c.u.). Cerebrocurin increased this indicator by 15.8 times (5.24 ± 0.002 c.u.), piracetam—by 82% (0.603 ± 0.0003 c.u.), angiolin—by 13.9 times (4.61 ± 0.004 c.u.), glutoredoxin—8.5 times (2.80 ± 0.002 c.u.), thiotriazoline—6.2 times (2.06 ± 0.001 c.u.), mexidol—2.3 times (0.77 ± 0.006 c.u.). The indices of HIF-1 α mRNA expression in rats after administration of cerebrocurin and angiolin are maximal and significantly exceed those of all experimental groups. The conducted studies show that modeling of prenatal hypoxia and its pharmacological correction changes the pattern of HIF-1 α



Citation: Aliyeva, O.G.; Belenichev, I.F.; Popazova, O.O.; Zidrashko, G.A. Pharmacological Modulation of Hif-1 α in the Cerebral Cortex of Rats after Chronic Prenatal Hypoxia. *Biol. Life Sci. Forum* **2022**, *19*, 9. <https://doi.org/10.3390/IECBS2022-12947>

Academic Editor: Pierluigi Zoccolotti

Published: 30 September 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

mRNA expression. An increase in the expression of HIF-1 α mRNA directly indicates the activation of certain genes of the cellular genome associated with the action of stimulating signals on the activation of adaptive-compensatory intracellular mechanisms in cells in response to the harmful effects of PH. Conclusions: Thus, HIF-1 α is a promising target for neuroprotection after PH exposure. Cerebrocurin and angiolin can be considered as promising agents for correcting the negative consequences of chronic PH in newborns.

Keywords: CNS; prenatal hypoxia; endogenous neuroprotection; HIF-1a

Supplementary Materials: The presentation material of this work is available online at <https://www.mdpi.com/article/10.3390/IECBS2022-12947/s1>.

Author Contributions: Conceptualization, methodology, I.F.B. and O.G.A.; conducting an experiment, O.G.A., O.O.P. and G.A.Z.; data curation, O.O.P.; writing—original draft preparation, O.G.A.; writing—review and editing, O.O.P. and G.A.Z.; supervision, project administration, I.F.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The experimental studies were carried out in accordance with the “Regulations on the Use of Animals in Biomedical Research” and with the European Convention on the Protection of Animals Used for Scientific and Other Purposes. The experiment was approved by the Bioethics Committee of Zaporizhzhia State Medical University.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data are available from the corresponding author upon reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.